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1. Introduction 
Hypertrophic cardiomyopathy (HCM) is a complex cardiac disease with unique 
pathophysiological characteristics and a great diversity of morphological, functional, and 
clinical features. HCM is defined as primary myocardial hypertrophy in the absence of 
aortic valve disease or significant hypertension (Elliott, 2008)  
 
 
Fig. 1. Magnetic resonance imaging; hypertrophic left and right ventricle. 
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Several observations suggest that the prevalence of HCM is globally 1 in 500 (Maron, 1994). 
The condition therefore seems to be a common genetic malformation of the heart. The 
clinical course varies markedly. Some patients remain asymptomatic throughout their whole 
lives, some have severe symptomatology of heart failure or angina pectoris, while others die 
suddenly even in the absence of previous symptoms. The annual mortality rate varies in 
different studies. In unselected populations, it has been reported to be about 1% (Elliott, 
2008). These observations suggest that a substantial proportion of patients with HCM has a 
more favourable course than previously believed. Two thirds of patients with HCM display 
evidence of obstruction in the left ventricular outflow tract (hypertrophic obstructive 
cardiomyopathy, HOCM), that is negatively associated with prognosis of the patients. 
During the last decade, technological developments in non-surgical treatment have 
provided new therapeutic options for patients with this disease. Recent changes have also 
generated considerable questions about the optimal management of HOCM and the role of 
percutaneous alcohol septal ablation (ASA) (Veselka, 2007). 
With respect to various clinical courses, it seems to be impossible to define precise guidelines 
for management. As in many diseases, it is often necessary to individualise therapy.  
2. Drug therapy of patients with hypertrophic obstructive cardiomyopathy 
Drug therapy is used as the initial measure for controlling cardiac symptoms that has resulted 
in functional limitation. Beta-blockers and verapamil have traditionally been administered on 
an empirical basis, relying on the patient´s subjective perception of benefit. Drug selection is 
based on preferences of individual physicians. Most favour beta-blockers over verapamil for 
use in initial treatment, although it is not of critical importance which drug is used first. 
There is no evidence that beta-blockers or verapamil protect patients with HOCM from 
sudden death. On the other hand, they are able to relieve symptoms in the majority of 
patients. Whether these drugs should be used prophylactically to delay disease progression 
and improve prognosis in asymptomatic patients has been a subject of debate for many 
years. The effectiveness of a prophylactic treatment has not been tested prospectively 
because study populations are small and traditional endpoints are infrequent (death, clinical 
deterioration). Accordingly, we reserve medical therapy only for symptomatic patients. 
3. Surgery to relieve the left ventricular obstruction  
The group of patients who have both a large outflow gradient and severe symptoms and 
also do not respond to medical treatment are the best candidates for surgery. Based on 
outstanding experience of several surgical centres worldwide, myectomy has become the 
primary therapeutic option for patients with severe symptoms and marked functional 
disability (McCully, 1996). Surgical reduction of the outflow gradient is achieved by 
removing a small amount of muscle (5 to 10 g) from the basal septum. Recently, some 
surgeons have performed more extended myectomies and reconstruction of the subvalvular 
mitral apparatus. In these cases, the septal myectomy deeply extends into the left ventricular 
cavity. Subsequently, both papillary muscles are mobilised and all hypertrophied muscular 
trabeculae are also resected.  Mitral valve replacement has also been used as an alternative 
therapy in selected patients, but the role of this operation remains unsettled. 
Surgery substantially reduces the basal outflow gradient in more than 90% of patients and 
provides large improvements in objective measures of symptoms and functional status. 
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However, the procedure requires extracorporeal circulation and great surgical experience. 
Mortality rates less than 2% are achieved only in heart centres with extensive surgical 
experience and numerous performed procedures. The effect of surgery on survival is not 
known. Accordingly, surgery is not performed in asymptomatic or mildly symptomatic patients.  
4. Cardiac pacing to relieve the left ventricular obstruction  
The role of cardiac pacing in reducing the left ventricular outflow gradient in HOCM was 
first reported more than 40 years ago (Gilgenkrantz, 1968). At the same time, it had been 
noticed that patients who developed left bundle branch block after septal myectomy had a 
better functional outcome. Sporadic reports over the years have culminated in the interest of 
cardiac pacing in the 1990s´. 
In the early 1990s, several observational studies reported that dual-chamber pacing with 
shortened A-V delay was associated with both substantial decrease in the outflow gradient 
and symptomatic improvement of patients unresponsive to drug treatment. However, the 
mechanisms by which pacing might reduce outflow gradient was not understood. Later, 
three more carefully controlled and randomised studies found the effects of cardiac pacing 
to be less favourable (Linde, 1999; Maron, 1999; Nishimura, 1997). These studies were 
randomised, double-blind and crossover. Subjective symptomatic improvement was 
reported with similar frequency by patients after three months pacing and after the same 
period without pacing. Objective measurements of exercise capacity (for example maximal 
oxygen consumption) with and without pacing did not differ significantly. These findings 
suggested that a placebo effect might play an important role in the symptomatic 
improvement reported by the paced patients. Currently, cardiac pacing cannot be regarded 
as a primary treatment for patients with HOCM, although a modest reduction in outflow 
gradient is achieved in a number of paced patients. Probably a small subset of patients could 
profit from pacing, but this effect is inconsistent and usually only modest. Therefore, further 
randomized, controlled trials should be undertaken to resolve the uncertainties surrounding 
the utility and efficacy of cardiac pacing in patients with HOCM. 
5. Alcohol septal ablation to relieve the left ventricular obstruction  
The idea of inducing a septal infarction by catheter techniques was suggested by the 
observation that myocardial function of selected areas of the left ventricle can be suppressed 
by balloon occlusion of the supplying artery during angioplasty. The outflow pressure 
gradient in HOCM decreased significantly when the first septal artery was temporarily 
occluded by an angioplasty balloon catheter (Sigwart, 1982).  This concept was also 
supported by observations that the outflow pressure gradient decreased after anterior 
myocardial infarction in HOCM patients. 
Sigwart published his experience with “non-surgical myocardial reduction” of three patients 
with HOCM in 1995 (Sigwart, 1995). However, at the same time, other centres in Germany 
also started with the same interventional procedure (Kuhn, 2010). Since then, several 
modifications of the original technique have been described. The majority of authors prefer 
an echocardiography-guided anatomical approach for identifying the target septal branch 
(Veselka, 2007), where the target septal branch is detected using myocardial contrast 
echocardiography (MCE). Estimation of the size of the septal vascular territory with MCE is 
accurate and safe. Using MCE, it is possible to delineate the perfusion bed of the septal 
perforators and predict the infarct size that follows the alcohol injection. 
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Fig. 2. Transthoracic echocardiography, apical 4-chamber view with optimal opacification of 
the basal interventricular septum by echocontrast medium. 
Recently, we have proposed the use of real-time myocardial contrast echocardiography with 
very low mechanical index that allows better delineation of the target area than 
conventional contrast echocardiography (Veselka, 2009). 
 
 
Fig. 3. Transthoracic echocardiography, apical 4-chamber view with real time myocardial 
contrast echocardiography utilizing power modulation and intracoronary injection of small 
amount of echocontrast agent. 
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There is a significant correlation between MCE septal area and reduction of ouflow gradient. 
In general, a higher biomarker level (extent of necrosis) was detected with larger sections of 
the infarcted septum. However, since alcohol injection is directed mainly to the portion of 
the septum causing the obstruction, many patients have a small defect with a large 
reduction of outflow gradient. Additionally, it has been found that MCE in 5 to 10% of cases 
shows contrast within myocardium away from the septal target area, indicating threatening 
misplacement of the myocardial necrosis. Accordingly, necrotisation of myocardium distant 
from the septal target area as a source of potentially fatal complications can be avoided by 
this approach. The introduction of echocardiographic guidance of ASA led to an 
improvement in haemodynamic results, despite a decrease in the infarcted septal area 
estimated by the maximal creatine kinase rise.  
5.1 Indication 
Accepted patient selection criteria for ASA were as follows: (1) anatomical findings of 
marked septal hypertrophy that projects from the LVOT; (2) dynamic obstruction of LVOT; 
(3) unresponsiveness to the medical therapy. There were no sufficient data available to 
confirm exact haemodynamic (pressure gradient > 50 mmHg), anatomical (septum thickness 
> 18 mm) or clinical (dyspnoea with NYHA class III or IV) criteria that resulted in a certain 
relaxation of indications in clinical practice. Patients with moderate symptoms were treated 
if they had high gradients and additional findings, such as recurrent exercise-induced 
syncope, markedly abnormal blood pressure response at exercise, paroxysmal atrial 
fibrillation or extremely high pressure gradient after provocative manoeuvres (Valsalva 
manoeuvre or use of nitrates). It is a very important question in clinical practice whether the 
increased risk of sudden cardiac death associated with LVOT obstruction justifies the use of 
ASA in slightly symptomatic or completely asymptomatic patients. At present, there are no 
sufficient data to answer this question. However, a relatively low risk of sudden death in 
asymptomatic patients with obstruction and none of the recognised risk factors for sudden 
death (1.ventricular tachycardia, 2. abnormal exercise blood pressure response, 3. family 
history of premature death, 4. unexplained syncope, 5. severe left ventricular hypertrophy in 
any myocardial segment > 30 mm) suggests that aggressive interventions are unjustified in 
this group. The situation in asymptomatic patients with obstruction and additional risk 
factors is less clear. The approach must be individualised. It seems to be reasonable to 
implant an AV-sequential implantable cardioverter-defibrillator (ICD) to try atrio-
ventricular sequential pacing to reduce obstruction for 6 months, and then to perform ASA 
if needed. Nevertheless, ASA as the primary treatment is still unjustified in this group of 
patients, given potential mortality and morbidity associated with this procedure. Patient 
preference should, of course, be considered in such discussion and surgical myectomy 
should be mentioned as the gold standard in most western countries.  
5.2 Alcohol septal ablation procedure 
We usually recommend the following course of ASA procedure. A temporary pacemaker is 
placed in the apex of the right ventricle in everyone except patients who already have a 
permanent dual-chamber pacemaker in place. However, fluctuation of the pacing threshold 
has to be anticipated if the lead is directed towards the septum, i.e., with the tip in proximity 
to the ablation lesion.  A multipurpose catheter is advanced through the aortic valve into the 
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apex of the left ventricle and intraventricular gradient is measured by a pull-back technique. 
A 6 or 7F guiding catheter is then engaged into the ostium of the left coronary artery. Initial 
angiography is performed to localise the origin of septal arteries. Over-the-wire balloon 
catheter is introduced over a coronary wire into one of the major and proximal septal 
perforators and inflated. Contrast medium is injected through the central balloon lumen to 
delineate the area supplied by the septal branch and to ensure that balloon inflation 
prevents spillage into the left anterior descending artery. Contrast myocardial 
echocardiography is performed to delineate the area to be infarcted (Figures 1 and 2) and to 
exclude contrast (and subsequently alcohol) deposition in remote myocardial regions like 
the left ventricular posterior wall or papillary muscles. The optimal septal branch is 
identified by opacification of the area in the basal septum that is adjacent to the zone of 
maximal acceleration of the outflow jet and includes the point of coaptation between the 
septum and anterior mitral leaflet. Usually, the target septal branch originates from the 
proximal segment of the left anterior descending artery. However, in exceptional cases, it 
originates from diagonal or intermediate branches of the left coronary artery. Depending on 
the septal artery size and septal thickness, 1 to 2 ml of absolute ethanol are very slowly (2 to 
3 minutes) instilled through the lumen of the inflated balloon catheter and left in place for 5 
minutes. After balloon deflation and removal, angiography is done to confirm the patency 
of the left anterior descending artery and occlusion of the target septal branch. Measurement 
of intraventricular gradient is usually performed by a multipurpose catheter and guiding 
catheter and/or Doppler echocardiography. The gradient should decrease at least to one 
half. 
 
 
Fig. 4. Pressure gradient between left ventricle and aorta before ASA. 
www.intechopen.com
 Management of Hypertrophic Obstructive Cardiomyopathy with a Focus on Alcohol Septal Ablation 
 
27 
 
 
 
 
 
 
Fig. 5. Hemodynamic finding after ASA with nearly elimination of pressure gradient after 
procedure. 
A temporary pacemaker is sutured in place. The patient is observed in the coronary care 
unit for at least 48 hours. If there is no high-degree atrioventricular block, the pacemaker 
lead is then removed.  
5.3 Complications 
In-hospital death, the most significant complication of ASA, is rare. Nevertheless, it ranges 
in the literature from 1 to 4%. However, some observations suggest that in skilled hands, the 
mortality rate is close to zero. 
Historically, the incidence of complete heart block following ASA has ranged from 0 to 40% 
with a mean value of 8 to 18% (Veselka, 2007). However, the original technique of ASA has 
undergone several modifications and lower occurrence of post-procedural complete heart 
block has been reported (Veselka, 2010). The most important trend in the continuously 
developing ASA technique involves the lowering of the alcohol dose (1 to 2 ml) injected in 
very small fractions (0.1 to 0.3 ml) (Veselka, 2005). Subsequent small infarctions are 
sufficient in reducing obstruction to a similar extent as larger infarctions induced by a 
higher dose of alcohol. Moreover, it seems to be likely that a low dose of alcohol is 
www.intechopen.com
 Cardiomyopathies – From Basic Research to Clinical Management 
 
28
associated with lower incidence of major post-procedural conduction disturbances and 
improved prognosis (Kuhn, 2008).  
The selection of appropriate patients for this procedure appears to be as important as the 
procedural ASA technique itself. Only highly symptomatic patients without the left bundle 
branch block should be treated by ASA because of high incidence of right bundle branch 
block following ASA. Unfortunately, the resulting complete heart block can occur with no 
previous symptoms within hours or days after the procedure. Therefore, based on our 
clinical experience, patients after uncomplicated ASA should be observed in the coronary 
care unit for at least 2 or 3 days and consequent telemetric monitoring should be considered 
for at least 1 week.  
To improve the risk stratification of complete heart block occurrence, Faber et al. proposed a 
scoring system based on baseline ECG, heart rate profile, severity of obstruction, peri-
interventional enzyme kinetics, and peri-interventional conduction problems that might 
discriminate patients with a high risk for permanent pacemaker dependency from those 
with a stable atrioventricular conduction after ASA (Faber, 2007).  
Sustained ventricular tachycardia has been rarely reported following ASA and only few 
reports have described it as an early post-procedural complication (Veselka, 2010). There is 
the hypothesis that the early post-procedural period can be compared to the same period 
after acute myocardial infarction, and the development of sustained ventricular arrhythmias 
after the ASA is not as rare as was thought before. It seems to be likely that a lower dose of 
alcohol with the minimising of the resulting necrosis (scar) is unable to entirely eliminate 
either occurrence of ventricular arrhythmias that are dependent on disorganised cellular 
architecture of myocardium or serious conduction abnormalities.  
Still, some uncertainty persists regarding the ICD indication for the prevention of sudden 
death in patients with post-procedural sustained ventricular arrhythmias, and no data are 
available regarding their predictive power. Nevertheless, based on both our clinical 
experience (and lack of scientific evidence), we do not consider early post-procedural 
ventricular arrhythmias to be a sufficient justification per se for an ICD implantation.  
A serious complication of ASA is a leakage of ethanol from the target septal branch into the 
left anterior descending artery. This potentially fatal complication is avoided by the use of a 
slightly over-sized angioplasty balloon catheter and a very careful septal branch 
angiography that precedes alcohol ablation. Additionally, the slow administration of alcohol 
per fractions and septal branch occlusion for 5 minutes after the last alcohol injection ensure 
the safe course of the procedure. 
Theoretically, the potential risk of ventricular septal rupture following ASA should be 
considered. Surprisingly, this serious complication is probably very rare, although it is 
possible that it is underreported in the literature. 
5.4 Results 
ASA has not been subjected to many randomised clinical trials. However, observational data 
from European and US centres over a 16-year follow-up are consistent, attributing a number 
of favourable effects to ASA that generally parallel that of surgery, including gradual and 
progressive reduction in outflow gradient over 3 to 12 months and alleviation of symptoms. 
The most important finding after ASA is an impressive symptomatic improvement during 
both short- and long-term follow-up that is consistently reported by all groups dealing with 
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ASA. The mean functional class improved very significantly from NYHA 2.5-3 to 1.2-1.6.  
Similarly, objective measurements showed an increase in exercise capacity and peak oxygen 
consumption. 
During ASA, an acute LVOT gradient reduction is followed by a significant LVOT gradient 
increase during the early post-procedural period and a continuous LVOT gradient decrease 
during the follow-up. The rapid post-procedural LVOT gradient decrease is probably 
associated mainly with stunning, myocardial necrosis and the change in the left ventricular 
ejection dynamics. The later pressure gradient decrease is caused by scarring and thinning 
of the basal septum, resulting in left ventricular remodelling (Veselka, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Transthoracic echocardiography, parasternal long axis view with impressive finding 
of subaortic obstruction. 
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Fig. 7. Transthoracic echocardiography, parasternal long axis view with thinning of the 
basal interventricular septum (arrow) three months following ASA. 
This haemodynamic course characterised by “down-up-down” changes in pressure gradient 
occurs in the majority of patients and is called the “biphasic” response. In most trials, the 
resting LVOT pressure gradient is reduced from 60 to 70 mmHg at baseline to 10 to 20 
mmHg at mid- or long-term follow-up.  
6. Conclusion 
At present, there is not a single therapy that should be applied to all patients with severely 
symptomatic HOCM unresponsive to medical management. There are benefits and 
disadvantages of both surgical myectomy and ASA. Septal myectomy requires specialised 
tertiary referral centres and is a more complex procedure than ASA. Furthermore, there is 
no cardio-thoracic surgical centre in our country that would be able to perform this 
procedure routinely. On the other hand, there are no sufficient data concerning the long-
term follow-up of patients after ASA. 
Further investigation is required to be able to identify the best responders for cardiac 
pacing, ASA and surgical myectomy and compare the results for the available methods. 
Mainly, a randomised study comparing myectomy and ASA would be needed. However, 
low incidence of end points would require extremely high number of participants and, 
therefore, such a study will probably not be performed. 
Currently, a decision concerning the best therapy of patients with HOCM must be 
individualised to each patient depending on their wishes and expectations, way of life, age 
and haemodynamics. Centres of excellence are able to perform both ASA and myectomy 
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very safely and effectively. Therefore, choice of the final therapy should be tailored for the 
individual patient treated in a particular centre. 
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